NASDAQ · AVBP
Healthcare · Biotechnology
$28.27
Down-$0.66 (-2.28%)
Updated Oct 3, 2026, 11:38 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AVBP
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
AVBP closed at $28.27 after 20 trading sessions, down 8.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $29.26 | $29.33 | $27.80 | $28.27 | 519.56K |
| Oct 1, 2026 | $29.99 | $30.64 | $28.81 | $28.93 | 591.79K |
| Sep 30, 2026 | $29.69 | $30.90 | $29.65 | $30.28 | 712.46K |
| Sep 29, 2026 | $29.30 | $30.05 | $28.80 | $29.54 | 780K |
| Sep 28, 2026 | $28.38 | $29.90 | $28.02 | $29.30 | 1.02M |
| Sep 25, 2026 | $30.16 | $30.55 | $28.43 | $28.45 | 653.15K |
| Sep 24, 2026 | $29.94 | $30.51 | $29.235 | $30.10 | 608.96K |
| Sep 23, 2026 | $30.32 | $31.49 | $29.84 | $30.30 | 1.21M |
| Sep 22, 2026 | $30.22 | $30.50 | $29.56 | $30.32 | 389.12K |
| Sep 21, 2026 | $29.17 | $31.155 | $28.20 | $29.74 | 937K |
| Sep 18, 2026 | $29.00 | $29.64 | $28.62 | $28.90 | 1.24M |
| Sep 17, 2026 | $28.24 | $28.45 | $27.84 | $28.36 | 456.43K |
| Sep 16, 2026 | $28.15 | $28.305 | $27.28 | $27.65 | 379.43K |
| Sep 15, 2026 | $28.51 | $28.745 | $27.70 | $27.97 | 337.27K |
| Sep 14, 2026 | $29.10 | $29.83 | $28.395 | $28.57 | 538.36K |
| Sep 11, 2026 | $29.16 | $29.21 | $28.15 | $29.00 | 1.13M |
| Sep 10, 2026 | $29.33 | $30.53 | $28.54 | $28.70 | 564.17K |
| Sep 9, 2026 | $30.02 | $30.26 | $29.40 | $29.79 | 280.14K |
| Sep 8, 2026 | $30.57 | $31.40 | $30.02 | $30.28 | 721.96K |
| Sep 4, 2026 | $30.79 | $31.45 | $30.595 | $30.95 | 182.98K |
The latest Smart Investors Daily articles mentioning AVBP.
Company
Market Activity
Research & News
AVBP research
Company profile and research snapshot.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | Citigroup | Buy | — |
| Aug 13, 2026 | BTIG | Buy | — |
| May 29, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 21, 2026
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
SeekingAlpha · Aug 27, 2026
ArriVent BioPharma is also advancing ARR-002, a novel dual-target therapy for patients with ovarian and endometrial cancers. Read more on AVBP stock here.
Benzinga · Aug 17, 2026
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $44 to $47.
Benzinga · Aug 13, 2026
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVBP.
